<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015847</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068443</org_study_id>
    <secondary_id>OHSU-6263</secondary_id>
    <secondary_id>OHSU-409</secondary_id>
    <secondary_id>NCI-2794</secondary_id>
    <secondary_id>OHSU-HEM-00072-LX</secondary_id>
    <nct_id>NCT00015847</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase I/II Dose-Finding Study to Determine the Safety, Tolerability, and Anti-Leukemic Effects of STI571 (NSC 716051) in Combination With Interferon-alpha in Patients With Chronic Myelogenous Leukemia in Chronic Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate and interferon alfa may interfere with the growth of the cancer
      cells. Combining imatinib mesylate with interferon alfa may kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of combining imatinib mesylate with
      interferon alfa in treating patients who have chronic myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of interferon alfa administered with imatinib
           mesylate in patients with chronic phase chronic myelogenous leukemia. (Phase I closed to
           accrual as of 7/9/03.)

        -  Determine the safety and tolerability of this regimen in this patient population.

        -  Determine the complete, major, and minor cytogenetic response rates and complete
           hematologic response rate in patients after 6 and 12 months of treatment with this
           regimen.

        -  Determine the molecular response (reverse transcriptase-polymerase chain reaction for
           bcr-abl) rate in patients who have a complete cytogenetic response after 6 and 12 months
           of treatment with this regimen.

        -  Determine the pharmacokinetics of this regimen in these patients.

      OUTLINE: This is a dose-escalation, multicenter study.

        -  Phase I (closed to accrual as of 7/9/03): Patients receive oral imatinib mesylate once
           daily beginning on day 1 and interferon alfa (IFN-A) subcutaneously once daily or 3
           times weekly beginning on day 14. Courses repeat every 35 days for up to 1 year in the
           absence of disease progression or unacceptable toxicity. After completion of 1 year of
           therapy, patients may receive additional therapy, provided that the patient is
           benefiting from imatinib mesylate. IFN-A is discontinued in patients who achieve a
           molecular remission that is confirmed on 2 successive bone marrow samples. Imatinib
           mesylate is discontinued in patients who achieve and maintain a molecular remission for
           2 years.

      Sequential dose escalation of IFN-A is followed by sequential dose escalation of imatinib
      mesylate. Cohorts of 3-6 patients receive escalating doses of IFN-A and then imatinib
      mesylate until the maximum tolerated dose (MTD) of the combination is determined. The MTD is
      defined as the dose preceding that at which 2 of 6 patients experience dose-limiting
      toxicity.

        -  Phase II: Patients receive imatinib mesylate and IFN-A as in phase I at the established
           MTD.

      Patients are followed for 30 days.

      PROJECTED ACCRUAL: Approximately 3-15 patients will be accrued for the phase I portion of
      this study. (Phase I closed to accrual as of 7/9/03.) A total of 40 patients will be accrued
      for the phase II portion of the study within 3-4 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Cytogenetic Response at 6 and 12 Months (Phase II)</measure>
    <time_frame>At 6 and 12 months during phase II</time_frame>
    <description>Cytogenetic response in terms of the percentage of Ph chromosome positive metaphases in bone marrow is defined as follows:
Complete* (0% Ph-positive cells) Partial* (1-34%) Minor (35-95%) None (96-100%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minor Cytogenetic Response at 6 and 12 Months (Phase II)</measure>
    <time_frame>At 6 and 12 months during phase II</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Hematologic Response at 6 and 12 Months (Phase II)</measure>
    <time_frame>At 6 and 12 months during phase II</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular Response in Patients With Complete Cytogenetic Response at 6 and 12 Months (Phase II)</measure>
    <time_frame>At 6 and 12 months during phase II</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related Toxicity (i.e., Grade 3 or 4 Nonhematologic Toxicity) as Measured by NCI CTCAE v3.0 (Phase I)</measure>
    <time_frame>12 Months</time_frame>
    <description>1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Cytogenetic Response After 6 and 12 Months of Treatment.</measure>
    <time_frame>6 and 12 months after treatment</time_frame>
    <description>Cytogenetic response in terms of the percentage of Ph chromosome positive metaphases in bone marrow is defined as follows:
Complete* (0% Ph-positive cells) Partial* (1-34%) Minor (35-95%) None (96-100%).
*Major cytogenetic response includes complete and partial cytogenetic response.</description>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <description>IFN-Î± will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.</description>
    <other_name>STI571</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Cytogenetically confirmed chronic myelogenous leukemia (CML)

               -  Less than 15% blasts in peripheral blood or bone marrow

               -  Less than 30% blasts and promyelocytes in peripheral blood or bone marrow

               -  Less than 20% basophils in blood or bone marrow

               -  Platelet count at least 100,000/mm^3

          -  No leukemia beyond bone marrow, blood, liver, or spleen

          -  No chloroma

          -  Phase I (closed to accrual as of 7/9/03):

               -  Philadelphia (Ph) chromosome-positive CML in chronic phase

          -  Phase II:

               -  Newly diagnosed Ph chromosome-positive CML in chronic phase

               -  Initial diagnosis within 6 months of study

               -  No prior therapy for CML except hydroxyurea and/or anagrelide hydrochloride

          -  Phase I (closed to accrual as of 7/9/03) and II:

               -  No identified sibling donors where allogeneic stem cell transplantation is
                  elected as first-line therapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

        Hepatic:

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST or ALT no greater than 2 times ULN

        Renal:

          -  Creatinine no greater than 1.5 times ULN

        Cardiovascular:

          -  No New York Heart Association class III or IV heart disease

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 methods of effective barrier contraception during and for
             at least 3 months after study participation

          -  No other serious uncontrolled medical condition

          -  No autoimmune disease

          -  No prior noncompliance to medical regimens or potential unreliability

          -  No prior grade 3 or greater non-hematologic toxicity due to prior interferon (phase I
             [closed to accrual as of 7/9/03])

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  See Disease Characteristics

          -  No prior bone marrow or peripheral blood stem cell transplantation

          -  At least 2 weeks since prior interferon alfa (phase I [closed to accrual as of
             7/9/03])

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 6 weeks since prior busulfan (phase I [closed to accrual as of 7/9/03] )

          -  At least 2 weeks since prior cytarabine (phase I [closed to accrual as of 7/9/03])

          -  No concurrent chemotherapy

          -  Concurrent hydroxyurea allowed during the first 3 months of study

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  At least 4 weeks since prior investigational agents other than imatinib mesylate
             (phase I [closed to accrual as of 7/9/03])

          -  No concurrent grapefruit juice

          -  Concurrent anagrelide hydrochloride allowed during the first 3 months of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J. Druker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>June 6, 2012</results_first_submitted>
  <results_first_submitted_qc>July 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2012</results_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Imatinib Mesylate</title>
          <description>Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Imatinib Mesylate</title>
          <description>Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Cytogenetic Response at 6 and 12 Months (Phase II)</title>
        <description>Cytogenetic response in terms of the percentage of Ph chromosome positive metaphases in bone marrow is defined as follows:
Complete* (0% Ph-positive cells) Partial* (1-34%) Minor (35-95%) None (96-100%).</description>
        <time_frame>At 6 and 12 months during phase II</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Cytogenetic Response at 6 and 12 Months (Phase II)</title>
          <description>Cytogenetic response in terms of the percentage of Ph chromosome positive metaphases in bone marrow is defined as follows:
Complete* (0% Ph-positive cells) Partial* (1-34%) Minor (35-95%) None (96-100%).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minor Cytogenetic Response at 6 and 12 Months (Phase II)</title>
        <time_frame>At 6 and 12 months during phase II</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complete Hematologic Response at 6 and 12 Months (Phase II)</title>
        <time_frame>At 6 and 12 months during phase II</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Molecular Response in Patients With Complete Cytogenetic Response at 6 and 12 Months (Phase II)</title>
        <time_frame>At 6 and 12 months during phase II</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Toxicity (i.e., Grade 3 or 4 Nonhematologic Toxicity) as Measured by NCI CTCAE v3.0 (Phase I)</title>
        <description>1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Toxicity (i.e., Grade 3 or 4 Nonhematologic Toxicity) as Measured by NCI CTCAE v3.0 (Phase I)</title>
          <description>1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Cytogenetic Response After 6 and 12 Months of Treatment.</title>
        <description>Cytogenetic response in terms of the percentage of Ph chromosome positive metaphases in bone marrow is defined as follows:
Complete* (0% Ph-positive cells) Partial* (1-34%) Minor (35-95%) None (96-100%).
*Major cytogenetic response includes complete and partial cytogenetic response.</description>
        <time_frame>6 and 12 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate</title>
            <description>Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Cytogenetic Response After 6 and 12 Months of Treatment.</title>
          <description>Cytogenetic response in terms of the percentage of Ph chromosome positive metaphases in bone marrow is defined as follows:
Complete* (0% Ph-positive cells) Partial* (1-34%) Minor (35-95%) None (96-100%).
*Major cytogenetic response includes complete and partial cytogenetic response.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Imatinib Mesylate</title>
          <description>Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination; 12 month follow-up was not carried out.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brian Druker</name_or_title>
      <organization>OHSU Knight Cancer Institute</organization>
      <phone>(503) 494 5596</phone>
      <email>drukerb@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

